Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sovilnesib in Advanced Solid Tumors
NCT04293094Phase 1Completed
- Sponsor
- Volastra Therapeutics
- Start
- Mar 2020
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 1, open-label trial of sovilnesib in solid tumor, triple-negative breast cancer (TNBC), serous ovarian carcinoma (SOC) and 1 more (3 arms), sponsored by Volastra Therapeutics. Primary endpoints: Dose Limiting Toxicities at 12 months, Treatment-emergent Adverse Events at 24 months and 5 more. Started Mar 2020; status: completed.
02
Drugs
sovilnesib
03
Conditions
solid tumortriple-negative breast cancer (TNBC)serous ovarian carcinoma (SOC)serous endometrial carcinoma (SEC)
Beyond the preview
Go deeper on NCT04293094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04293094.